Cargando…

Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway

Glibenclamide displays an anti-inflammatory response in various pulmonary diseases, but its exact role in lipopolysaccharide- (LPS-) induced acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) remains unknown. Herein, we aimed to explore the effect of glibenclamide in vivo and in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jie, Yang, Jiawen, Huang, Xiaofang, Xiu, Huiqing, Bai, Songjie, Li, Jiahui, Cai, Zhijian, Chen, Zhanghui, Zhang, Shufang, Zhang, Gensheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856806/
https://www.ncbi.nlm.nih.gov/pubmed/35185385
http://dx.doi.org/10.1155/2022/8457010
_version_ 1784653919986647040
author Yang, Jie
Yang, Jiawen
Huang, Xiaofang
Xiu, Huiqing
Bai, Songjie
Li, Jiahui
Cai, Zhijian
Chen, Zhanghui
Zhang, Shufang
Zhang, Gensheng
author_facet Yang, Jie
Yang, Jiawen
Huang, Xiaofang
Xiu, Huiqing
Bai, Songjie
Li, Jiahui
Cai, Zhijian
Chen, Zhanghui
Zhang, Shufang
Zhang, Gensheng
author_sort Yang, Jie
collection PubMed
description Glibenclamide displays an anti-inflammatory response in various pulmonary diseases, but its exact role in lipopolysaccharide- (LPS-) induced acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) remains unknown. Herein, we aimed to explore the effect of glibenclamide in vivo and in vitro on the development of LPS-induced ALI in a mouse model. LPS stimulation resulted in increases in lung injury score, wet/dry ratio, and capillary permeability in lungs, as well as in total protein concentration, inflammatory cells, and inflammatory cytokines including IL-1β, IL-18 in bronchoalveolar lavage fluid (BALF), and lung tissues, whereas glibenclamide treatment reduced these changes. Meanwhile, the increased proteins of NLRP3 and Caspase-1/p20 after LPS instillation in lungs were downregulated by glibenclamide. Similarly, in vitro experiments also found that glibenclamide administration inhibited the LPS-induced upregulations in cytokine secretions of IL-1β and IL-18, as well as in the expression of components in NLRP3 inflammasome in mouse peritoneal macrophages. Of note, glibenclamide had no effect on the secretion of TNF-α in vivo nor in vitro, implicating that its anti-inflammatory effect is relatively specific to NLRP3 inflammasome. In conclusion, glibenclamide alleviates the development of LPS-induced ALI in a mouse model via inhibiting the NLRP3/Caspase-1/IL-1β signaling pathway, which might provide a new strategy for the treatment of LPS-induced ALI.
format Online
Article
Text
id pubmed-8856806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88568062022-02-19 Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway Yang, Jie Yang, Jiawen Huang, Xiaofang Xiu, Huiqing Bai, Songjie Li, Jiahui Cai, Zhijian Chen, Zhanghui Zhang, Shufang Zhang, Gensheng Mediators Inflamm Research Article Glibenclamide displays an anti-inflammatory response in various pulmonary diseases, but its exact role in lipopolysaccharide- (LPS-) induced acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) remains unknown. Herein, we aimed to explore the effect of glibenclamide in vivo and in vitro on the development of LPS-induced ALI in a mouse model. LPS stimulation resulted in increases in lung injury score, wet/dry ratio, and capillary permeability in lungs, as well as in total protein concentration, inflammatory cells, and inflammatory cytokines including IL-1β, IL-18 in bronchoalveolar lavage fluid (BALF), and lung tissues, whereas glibenclamide treatment reduced these changes. Meanwhile, the increased proteins of NLRP3 and Caspase-1/p20 after LPS instillation in lungs were downregulated by glibenclamide. Similarly, in vitro experiments also found that glibenclamide administration inhibited the LPS-induced upregulations in cytokine secretions of IL-1β and IL-18, as well as in the expression of components in NLRP3 inflammasome in mouse peritoneal macrophages. Of note, glibenclamide had no effect on the secretion of TNF-α in vivo nor in vitro, implicating that its anti-inflammatory effect is relatively specific to NLRP3 inflammasome. In conclusion, glibenclamide alleviates the development of LPS-induced ALI in a mouse model via inhibiting the NLRP3/Caspase-1/IL-1β signaling pathway, which might provide a new strategy for the treatment of LPS-induced ALI. Hindawi 2022-02-11 /pmc/articles/PMC8856806/ /pubmed/35185385 http://dx.doi.org/10.1155/2022/8457010 Text en Copyright © 2022 Jie Yang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yang, Jie
Yang, Jiawen
Huang, Xiaofang
Xiu, Huiqing
Bai, Songjie
Li, Jiahui
Cai, Zhijian
Chen, Zhanghui
Zhang, Shufang
Zhang, Gensheng
Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway
title Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway
title_full Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway
title_fullStr Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway
title_full_unstemmed Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway
title_short Glibenclamide Alleviates LPS-Induced Acute Lung Injury through NLRP3 Inflammasome Signaling Pathway
title_sort glibenclamide alleviates lps-induced acute lung injury through nlrp3 inflammasome signaling pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856806/
https://www.ncbi.nlm.nih.gov/pubmed/35185385
http://dx.doi.org/10.1155/2022/8457010
work_keys_str_mv AT yangjie glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT yangjiawen glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT huangxiaofang glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT xiuhuiqing glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT baisongjie glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT lijiahui glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT caizhijian glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT chenzhanghui glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT zhangshufang glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway
AT zhanggensheng glibenclamidealleviateslpsinducedacutelunginjurythroughnlrp3inflammasomesignalingpathway